Clinical trials: Overall Response Rate
Progress-free Survival, Overall Response Rate
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China.
- Conditions
- Progress-free Survival, Overall Response Rate, Adverse Events
- Trial name
- HOPES (NCT01291667)
- Volunteers
- 330 people
- Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd.